| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.86 [0.78, 0.94] | | < 1 | | 0% | 4 studies (4/-) | 99.9 % | some concern | not evaluable | moderate | crucial | - |
| progression or deaths (PFS) | 1.02 [0.73, 1.44] | | < 1 | | 93% | 4 studies (4/-) | 44.5 % | some concern | not evaluable | moderate | important | - |
| DCR | 0.62 [0.43, 0.89] | | > 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.92 [0.44, 1.95] | | > 1 | | 94% | 4 studies (4/-) | 41.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.74 [0.33, 1.67] | | < 1 | | 51% | 3 studies (3/-) | 76.5 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.47 [0.10, 2.17] | | < 1 | | 98% | 3 studies (3/-) | 83.4 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.24 [0.67, 2.31] | | < 1 | | 0% | 3 studies (3/-) | 24.5 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.53 [0.16, 1.78] | | < 1 | | 94% | 3 studies (3/-) | 84.7 % | some concern | not evaluable | moderate | non important | - |
| SAE (any grade) | 1.26 [0.86, 1.83] | | < 1 | | 0% | 1 study (1/-) | 11.9 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.31 [0.54, 3.21] | | < 1 | | 85% | 2 studies (2/-) | 27.5 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 1.80 [1.33, 2.44] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.62 [0.17, 2.32] | | < 1 | | 97% | 4 studies (4/-) | 76.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.75 [0.13, 4.28] | | < 1 | | 98% | 2 studies (2/-) | 62.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 2.25 [0.15, 33.86] | | < 1 | | 32% | 2 studies (2/-) | 28.1 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 0.76 [0.13, 4.44] | | < 1 | | 98% | 2 studies (2/-) | 61.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.12 [1.55, 2.90] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.61 [0.15, 2.53] | | < 1 | | 93% | 3 studies (3/-) | 75.4 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.55 [0.21, 1.42] | | < 1 | | 48% | 3 studies (3/-) | 89.2 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.73 [0.09, 6.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.53 [0.21, 1.34] | | < 1 | | 69% | 3 studies (3/-) | 91.0 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.71 [0.27, 1.90] | | < 1 | | 77% | 3 studies (3/-) | 75.0 % | some concern | not evaluable | moderate | non important | - |
| Dizziness TRAE (grade 3-4) | 0.73 [0.09, 6.31] | | < 1 | | 0% | 2 studies (2/-) | 61.0 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 9.86 [0.54, 180.88] | | < 1 | | 0% | 1 study (1/-) | 6.4 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.85 [0.27, 2.66] | | < 1 | | 78% | 3 studies (3/-) | 60.8 % | some concern | not evaluable | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.73 [1.04, 2.86] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 1.81 [0.97, 3.36] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.94 [0.18, 21.47] | | < 1 | | 0% | 2 studies (2/-) | 29.6 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 2.38 [0.83, 6.77] | | < 1 | | 0% | 1 study (1/-) | 5.3 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 1.18 [0.36, 3.88] | | < 1 | | 0% | 1 study (1/-) | 39.4 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.87 [1.61, 5.12] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 2.43 [0.23, 25.98] | | < 1 | | 34% | 2 studies (2/-) | 23.2 % | low | not evaluable | high | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.20 [0.01, 4.07] | | < 1 | | 77% | 2 studies (2/-) | 85.1 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 0.60 [0.21, 1.75] | | < 1 | | 76% | 3 studies (3/-) | 82.3 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.66 [0.26, 1.66] | | < 1 | | 88% | 3 studies (3/-) | 81.1 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.04 [0.32, 3.44] | | < 1 | | 60% | 3 studies (3/-) | 47.2 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.37 [0.82, 2.31] | | < 1 | | 0% | 3 studies (3/-) | 11.7 % | some concern | not evaluable | moderate | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 1.33 [0.50, 3.53] | | < 1 | | 10% | 2 studies (2/-) | 28.5 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.44 [0.11, 18.83] | | < 1 | | 0% | 2 studies (2/-) | 39.1 % | low | not evaluable | high | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 5.92 [0.71, 49.31] | | < 1 | | 0% | 1 study (1/-) | 5.1 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 13.96 [1.83, 106.45] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.36 [1.79, 10.66] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.34 [0.02, 6.97] | | < 1 | | 77% | 2 studies (2/-) | 75.7 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 1.00 [0.38, 2.62] | | < 1 | | 46% | 3 studies (3/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.57 [0.23, 1.40] | | < 1 | | 57% | 3 studies (3/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 1.22 [0.17, 8.73] | | < 1 | | 0% | 2 studies (2/-) | 42.0 % | low | not evaluable | high | non important | - |
